# Larimar Therapeutics, Inc. (LRMR)

> Source: Nexqual · https://nexqual.com/LRMR · data as of 2026-11-18 19:54 UTC · cite as "Nexqual, Larimar Therapeutics, Inc. (LRMR), nexqual.com/LRMR" · informational, not investment advice.

## What changed for LRMR since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).

- Larimar Therapeutics, Inc. (LRMR) stock went from USD 3.62 (close of the week of Aug 25, 2025, split-adjusted) to USD 3.2, a -11.5% price change; the S&P 500 (SPY) moved +14.7% over the same period.
- Analyst actions on LRMR in the last 120 days: 1 (0 upgrades or target raises, 1 downgrades or target cuts); most recent Wedbush, Aug 5, 2026.

**Price:** USD 3.21 (+7.19% today) · US market open, as of November 18, 2026 at 19:54 UTC; quotes may be delayed. Prev close 2.99 · day 2.93–3.35 · 52w 1.92–6.42 · market cap $335M · NGM

## Key facts
- Insider open-market purchases, last ~7 months: 9 Form 4 filings, $559K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.82 on a 1–5 scale) (11 analysts), mean target USD 14.2 (range 5–26).
- Total return with dividends: 1Y -5.5% vs S&P 500 +11.8%; 5Y -68.7% vs S&P 500 +66.5%.
- Latest earnings report: 2026-11-16 (next date not yet announced).
- Dividend: LRMR paid no cash dividend in the last five years.
- Short interest: 15.50% of float (as of 2026-10-30), 7.1 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$50.5M | -$36.5M | -$41.8M | -$90.9M | -$172M | -$162M |
| Net income | -$50.6M | -$35.4M | -$36.9M | -$80.6M | -$166M | -$156M |
| EPS (diluted) | -$2.95 | -$1.37 | -$0.84 | -$1.32 | — | — |
| Free cash flow | -$42.4M | -$27.7M | -$33.6M | -$71.3M | -$113M | — |
| Cash + short-term investments | — | $118M | $86.8M | $184M | $137M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Sep 30, 2026)
P/B 3.3x · Earnings yield -46.53%

## Insider purchases (SEC Form 4, open-market, last ~7 months)
9 purchases, $559K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-11-16 | Sherman Jeffrey W | Director | 3,289 | $10K | 3.06 | Too little history (no open-market trades in 2023–2025) |
| 2026-11-12 | Hamilton Thomas Edward | Director | 70,000 | $187K | 2.67 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-11-11 | Ben-Maimon Carole | President and CEO | 18,050 | $50K | 2.77 | Too little history (no open-market trades in 2024 or 2025) |
| 2026-11-11 | Thomas Frank E | Director | 8,000 | $22K | 2.73 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-11-11 | Truitt Joseph | Director | 3,500 | $10K | 2.8 | Too little history (no open-market trades in 2024 or 2025) |
| 2026-11-11 | Harlow John B. Jr. | President and COO | 17,800 | $50K | 2.8 | Too little history (no open-market trades in 2023–2025) |
| 2026-11-11 | Celano Michael | Chief Financial Officer | 18,460 | $50K | 2.71 | Too little history (no open-market trades in 2024 or 2025) |
| 2026-11-11 | Shankar Gopi | Chief Development Officer | 5,000 | $14K | 2.71 | Too little history (no open-market trades in 2024 or 2025) |
| 2026-07-06 | Hamilton Thomas Edward | Director | 50,000 | $167K | 3.34 | Too little history (no open-market trades in 2023 or 2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.82 on a 1–5 scale), 11 analysts; mean target USD 14.2 (low 5, high 26).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-05 | Wedbush | Target lowered | Outperform | $12 → $11 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-11-18) | 5Y (from 2021-11-15) |
|---|---|---|
| Total return | -5.5% | -68.7% |
| S&P 500 (SPY) | +11.8% | +66.5% |
| Per year | -5.5% | -20.7% |
| Volatility (annualized) | 93.4% | 95.2% |
| Max drawdown | -66.6% (Feb 2026→Oct 2026) | -86.1% (Dec 2021→Aug 2022) |

## Dividends
LRMR paid no cash dividend in the last five years.

## Short interest
10,538,346 shares sold short, 15.50% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 15,369,771 shares (-31.4%). Days to cover: 7.1 (short shares ÷ average daily volume).

## Peers (Biotechnology)
KOD (Kodiak Sciences Inc) USD 97.48 +0.70% · BLTE (Belite Bio, Inc) USD 155.61 -1.34% · IBRX (ImmunityBio, Inc.) USD 6.74 +7.67% · ORKA (Oruka Therapeutics, Inc.) USD 95.82 -0.52% · IMVT (Immunovant, Inc.) USD 33.33 +0.36% · CGON (CG Oncology, Inc.) USD 80.12 +1.49%

## More
Full page: https://nexqual.com/LRMR · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in LRMR's own 10-K filed 2026-03-19 (https://www.sec.gov/Archives/edgar/data/1374690/000119312526115878/lrmr-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | KBI Biopharma | "The drug substance which is in frozen liquid form for nomlabofusp is currently manufactured for us by KBI Biopharma, Inc. ("KBI")." |
| Supplier | Lonza | "Additional comparability of the drug substance manufactured by Lonza will need to be performed and reviewed by the FDA and other regulatory authorities in order to use the Lonza-manufactured drug substance in clinical an…" |

Other companies that name LRMR in their own reports (relationship from LRMR's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Lexeo Therapeutics, Inc. (LXEO) | 10-K 2026-03-30 | "With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and…" |

## Company outlook (8-K filed 2026-11-16)

- "The Company projects its cash runway into late Q2 2027."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-12-31) | $-0.33 | $-0.38 | +$0.05 | $0 | 6 |
| Next quarter (ends 2027-03-31) | $-0.36 | $-0.39 | +$0.03 | $0 | 4 |
| Current fiscal year (ends 2026-12-31) | $-1.18 | $-1.35 | +$0.17 | $0 | 4 |
| Next fiscal year (ends 2027-12-31) | $-0.91 | $-1.06 | +$0.15 | $38.8M | 8 |

## Options: expected move (Cboe, 15-min delayed)

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 2 | 262.1% | ±38.1% |
| 2026-12-18 | 30 | 171.6% | ±34.8% |
| 2027-01-15 | 58 | 90.0% | ±43.9% |
| 2027-02-19 | 93 | 94.5% | ±42.1% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Nov 16, 2026 | Quarter ended Sep 30, 2026 | −$0.29 | −$0.36 | Beat +19.4% | -1.0% |
| Nov 9, 2026 | Quarter ended Sep 30, 2026 | −$0.29 | −$0.36 | Beat +19.4% | +12.6% |
| Aug 4, 2026 | Quarter ended Jun 30, 2026 | −$0.30 | −$0.38 | Beat +21.1% | +3.0% |
| May 14, 2026 | Quarter ended Mar 31, 2026 | −$0.31 | −$0.59 | Beat +47.5% | -12.7% |
| Mar 19, 2026 | Quarter ended Dec 31, 2025 | −$0.73 | −$0.55 | Miss −32.7% | +4.4% |
| Jan 12, 2026 | Quarter ended Dec 31, 2025 | −$0.73 | −$0.55 | Miss −32.7% | +0.0% |
| Nov 5, 2025 | — | — | — | — | -8.7% |
| Aug 14, 2025 | — | — | — | — | +7.8% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-11-16 | 10-Q | Quarterly report · period ended Sep 30, 2026 | https://www.sec.gov/Archives/edgar/data/1374690/000119312526462242/0001193125-26-462242-index.htm |
| 2026-11-16 | Schedule 13G | RTW Investments, LP, Roderick Wong: 5.6% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1374690/000149321526000194/0001493215-26-000194-index.htm |
| 2026-11-16 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1374690/000119312526462054/0001193125-26-462054-index.htm |
| 2026-11-09 | 8-K | Quarterly results; Other material event — “Press Release On November 9, 2026, the Company issued a press release announcing that the Company completed its rolling Biologics License Application submission to the U.S. Food and Drug Administration seeking accelerated approval of nomlabofusp for the treatment of patients with Friedreich's ataxia. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Corporate Presentation On November 9, 2026, the Company posted on its website an…” | https://www.sec.gov/Archives/edgar/data/1374690/000119312526453586/0001193125-26-453586-index.htm |
| 2026-09-29 | 8-K | Director or executive officer change, or pay arrangement — “The Board of Directors (the "Board") of Larimar Therapeutics, Inc. (the "Company") appointed John B. Harlow, Jr. as the Company's President and Chief Operating Officer pursuant to the terms of an employment agreement with Mr. Harlow (the "Employment Agreement"), effective as of September 29, 2026 (the "Effective Date"). Prior to joining the Company, Mr. Harlow, age 51, served as the Chief Commercial Officer at Esperion Therapeutics, Inc. (formerly Nasdaq: ESPR), a commercial stage biopharmaceutical company focused…” | https://www.sec.gov/Archives/edgar/data/1374690/000119312526407331/0001193125-26-407331-index.htm |
| 2026-08-04 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1374690/000119312526331529/0001193125-26-331529-index.htm |
| 2026-08-04 | 8-K | Quarterly results; Other material event — “On August 4, 2026, the Company posted on its website an updated slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.” | https://www.sec.gov/Archives/edgar/data/1374690/000119312526331516/0001193125-26-331516-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.
